Mevr. V schreef op 22 juli 2021 21:50:
Goedenavond,
Conestat alfa as
prophylactic treatment for idiopathic non-histaminergic acquired angioedema
Het primaire doel van deze exploratieve studie is om te testen of profylactische behandeling met conestat alfa de aanvalsfrequentie van angio-oedeem by patiënten met idiopatisch non-histaminerg verworven angio-oedeem verminderd.
Scope of the trialProphylaxis Yes
Therapy Yes
Therapeutisch exploratory (Phase II) Yes
Initial estimate of the duration of the trialIn the Member State concerned years 2
- Name of Sponsor University Medical Center Utrecht
- Name of organisation providing support Pharming Group N.V.,
- Ruconest 2100 U powder for solution for injection
Date of Competent Authority Decision 2017-04-06
End of Trial Status Ongoing
The status of studies in GB is no longer updated from 1.1.2021www.clinicaltrialsregister.eu/ctr-sea...